Ms. Petrovic has served as our President and Chief Executive Officer since January 1, 2019 and has served on our Board of Directors since September 2018. Prior to becoming Chief Executive Officer, she served as Insulet’s President and Chief Operating Officer from October 2016 to December 31, 2018. From February 2016 to October 2016, she served as our Executive Vice President and President, Diabetes Products, and from February 2015 to February 2016, she served as our Chief Commercial Officer. From 2013 to 2015, Ms. Petrovic served as President and Chief Executive Officer of Clinical Innovations, LLC, a developer and manufacturer of medical devices and diagnostics for women’s health. From 2000 to 2013, she served in a number of key roles at Hologic, Inc. and Cytyc Corporation, which merged with Hologic in October 2007, including Vice President and General Manager of Hologic’s GYN Surgical Products division, as well as various sales and marketing leadership roles in the U.S. and Europe. Ms. Petrovic earned her Bachelor of Science in Biology from the University of Wisconsin.
Dr. Abdel-Malek has served as our Executive Vice President and Chief Technology Officer since February 2018. From March 2016 to February 2018, he served as our Senior Vice President, Advanced Technology and Engineering. From 2015 to 2016, he served as President of Frictionless Life Analytics, Inc., a business development and technology advisory and consultancy company, enabling the growth of start-up ventures focused on Internet of Things (IoT) platforms and solutions. From 2012 to 2015, Dr. Abdel-Malek served as Vice President, Engineering of Qualcomm Life, Inc., a mobile healthcare solutions company. From 1988 to 2012, he held various roles at General Electric, including General Manager - Global Services Technology at GE Healthcare. Dr. Abdel-Malek brings over 20 years of experience as a senior executive leading healthcare teams to develop profound technology breakthroughs that optimize services. Dr. Abdel-Malek holds a Bachelor of Science, Systems and Biomedical Engineering from Cairo University and a Ph.D in Biomedical Engineering from the University of Southern California.
Mr. Alpuche has served as our Executive Vice President and Chief Operating Officer since February 2019. Prior, he served as our: Executive Vice President and Chief Operations Officer from February 2018 to February 2019; Executive Vice President, Global Manufacturing and Operations from February 2017 to February 2018; and Senior Vice President, Global Manufacturing and Operations from February 2016 to February 2017. From 2012 to February 2016, Mr. Alpuche served as an independent consultant for both domestic and international companies in the food, beverage and chemical industries. Previously, he spent thirty years at PepsiCo in leadership roles of increasing responsibility overseeing domestic and international plant operations. Earlier in his career at PepsiCo, he held a number of management roles in plant operations, product management and quality control. Most recently, he served as PepsiCo’s Senior Vice President of North America Beverages, and before that he held the position of Vice President and General Manager, Concentrate Operations, Asia and Americas. Mr. Alpuche holds a Bachelor of Science in Business Administration from Delaware Valley College and obtained an Executive Master of Science in Organizational Management from the University of Pennsylvania.
Mr. Benjamin has served as our Senior Vice President, Research and Development since February 2018. From February 2016 to January 2018 he served as Vice President, Procurement and Supplier Development, and from June 2015 to January 2016 Mr. Benjamin served as Director, Business Development. Prior to joining Insulet, Mr. Benjamin held roles of increasing responsibility spanning R&D, Manufacturing, and Quality with Abbott Laboratories. Mr. Benjamin earned a Bachelor of Science in Industrial Engineering and Operations Research from the University of California at Berkeley, a Master of Engineering in Bioengineering from the University of California at San Diego, and a Master of Business Administration from Harvard Business School.
Mr. Christensen has served as our Executive Vice President and Chief Commercial Officer since February 2019. Prior, he served as our Senior Vice President and Chief Commercial Officer since May 2017. He brings more than 20 years of commercial experience to Insulet. Mr. Christensen joins the Company from Myriad Genetics, where he served as General Manager of Preventive Care, the company's largest business unit, leading a team of more than 350 employees across all commercial functions. Prior to Myriad Genetics, Mr. Christensen held a series of executive positions at Hologic Corporation, including Vice President of Sales and Marketing of its Gynecologic Surgical Products division. Prior to Hologic, he led key market development and sales teams at Cytyc Corporation. Mr. Christensen earned a B.S. in Business Management from Utah Valley University and received an MBA from the University of Utah.
Ms. Gordon has served as our Vice President, Investor Relations and Corporate Communications since January 2015. Prior to joining Insulet, she served in a number of roles of increasing responsibility during her 10 years at Hologic, Inc. and Cytyc Corporation (which merged with Hologic in October 2007), notably seven years as Hologic’s Vice President, Investor Relations and Corporate Communications and prior as Assistant Corporate Controller and Director of SEC Reporting and Technical Accounting at Cytyc. Prior to joining Cytyc, Ms. Gordon served in the audit practice at Deloitte & Touch for 11 years. Ms. Gordon earned her B.A. in Business Administration, with concentrations in Accounting and Economics, from Clark University and is a certified public accountant.
Mr. Kapples has served as our Senior Vice President, Secretary and General Counsel since March 2019. From 2015 to 2018, he served as Vice President, Secretary and General Counsel at GCP Applied Technologies, Inc. Prior, Mr. Kapples served as Vice President and Corporate Secretary of Covidien plc from 2006 to 2015, which was acquired by Medtronic plc. in 2015. At Covidien, he was responsible for building the Company’s legal structure and compliance framework, as well as advising on strategic transactions and global partnerships. From 1994 to 2006, Mr. Kapples served in various roles of increasing responsibility at Raytheon Company, including Assistant General Counsel and Secretary, and from 1985 to 1993 he was a Corporate Associate at Sullivan & Worcester LLP. Mr. Kapples earned both his Bachelor of Arts in English and his Juris Doctor from Georgetown University. He is a member of the Massachusetts Bar Association and the Society of Corporate Secretaries & Governance Professionals.
Dr. Trang Ly has served as our Senior Vice President and Medical Director since February 2018. From September 2016 to February 2018, she served as our Vice President and Medical Director. Dr. Ly is a renowned expert in artificial pancreas and diabetes technologies. Most recently, she served as Clinical Assistant Professor in the Division of Pediatric Endocrinology, Stanford University School of Medicine. Prior to her time at Stanford, Dr. Ly was a Pediatric Endocrinologist in the Department of Endocrinology and Diabetes at Princess Margaret Hospital for Children in Perth, Australia. Dr. Ly holds a Bachelor of Medicine and Surgery, a Diploma of Child Health and a PhD in Pediatrics from the University of Western Australia. She is also a fellow of the Royal Australasian College of Physicians, with specialist qualification in Pediatric Endocrinology.
Mr. McMillan has served as our Executive Vice President, Chief Financial Officer since March 2019. From January 2015 to February 2019, he was Chief Financial Officer and Vice President of Finance of the Minimally Invasive Therapies Group at Medtronic, where he managed an $8 billion revenue business with greater than 20,000 employees and a global Finance team. He previously held a variety of leadership positions at Covidien from November 2006 until Medtronic’s acquisition of the company in January 2015, including Chief Financial Officer and Vice President of Finance of the Medical Devices Group & U.S., Chief Financial Officer and Vice President of Finance of the Surgical Solutions Business Unit, and Vice President Finance and Controller of the Respiratory and Monitoring Solutions Business Unit. Mr. McMillan started his career in accounting, audit, financial analysis and investor relations positions at various institutions. Mr. McMillan earned his Bachelor of Science in Business Administration from Merrimack College and a Master of Business Administration from the Bentley University McCallum Graduate School of Business.
Mr. Spears has served as our Senior Vice President, Quality and Regulatory Affairs since February 2017. From July 2015 to February 2017, he served as our Senior Vice President, Quality, Regulatory and Clinical Affairs. From 2011 to 2015, Mr. Spears served as Vice President, Quality Assurance & Regulatory Affairs at Covidien, which was acquired by Medtronic in 2015. From 2006 to 2011, Mr. Spears served as Vice President, Quality Assurance at Covidien. From 1999 to 2006, he had several years of progressively broader assignments at Covidien, then known as Tyco Healthcare. Mr. Spears also served as a paralegal at two law firms over an 11-year period. He earned his Bachelor of Arts from the University of Tennessee and a Master of Business Administration from the University of South Carolina.